Posted by Michael Wonder on 11 Feb 2025
Gilead’s breast cancer treatment Trodelvy passes drug reimbursement panel
7 February 2025 - Gilead's triple negative breast cancer treatment Trodelvy (trastuzumab govitecan) had surmounted a significant hurdle for health insurance coverage.
It is the first medicine allowed to be elastically applied by the incremental cost effectiveness ratio’s threshold value, passing the Pharmaceutical Reimbursement Evaluation Committee under the Health Insurance Review and Assessment Service.
